Summary code for ocular herpes simplex

JOHN McKINNON*, JAMES MCcGILL†, AND BARRIE R. JONES
From the Department of Clinical Ophthalmology, Institute of Ophthalmology, Moorfields Eye Hospital, London

Herpes simplex virus is a major cause of serious eye disease. Despite advances in antiviral therapy many patients experience exacerbations of the disease with progressive deterioration in their condition requiring frequent and long-continued ophthalmic attention. The resulting morbidity and loss of work constitutes a major social and economic disruption.

The character of herpetic disease may change in different directions in different patients over a period of time. Many patterns of disease are possible; but at present there is no way of predicting which patients presenting with dendritic ulceration are at particular risk of developing disciform keratitis, recurrent ulceration, corneal abscess formation, or herpetic uveitis.

The sequential pattern of herpetic disease is important in assessment of the individual patient and in determining correct management at each point: it probably also has prognostic and epidemiological significance and may be related to the type of herpes virus or even to strain differences in the agent.

The complexity and diversity of possible sequences and combinations of events have hitherto made it difficult to comprehend the entire historical pattern of each patient’s case, and exceedingly difficult to communicate a grasp of each case to other clinicians, or to analyse large-scale data for the existence of sequential patterns.

To overcome these difficulties in assessment and obstacles to communication we have devised a simple coding of the main morphological variants of herpetic disease, its treatment and complications. This code makes it easy to maintain a progressive summary of each case and greatly facilitates the rapid evaluation of essential data, at each decision-making point during management. Furthermore, it offers considerable facility in recording, analysing, and communicating the complex historical data to others.

*Present address: c/o Public Hospital, Nelson, New Zealand
†Southampton Eye Hospital, Wilton Avenue, Southampton S09 4XW

Address for reprints: Professor Barrie R. Jones, Institute of Ophthalmology, Moorfields Eye Hospital, City Road, London EC1V 2PD

Code and definitions

A. HERPETIC LESIONS OF VARIOUS MORPHOLOGY

1. Skin

   LV    — typical herpetic lid vesicles
   SV    — typical herpetic skin vesicles occurring beyond the lids.

2. Conjunctiva

   HC    — herpetic conjunctivitis
   An acute follicular conjunctivitis with regional lymphadenopathy. Frequently with SV (skin vesicles) or LV (lid vesicles) and sometimes a superficial punctate keratitis.

3. Superficial cornea

   HPK   — herpetic punctate keratitis
   Fine granular epithelial spots which coalesce to form irregularly-shaped lesions which stain with fluorescein. Frequently with subepithelial infiltration
   AU    — amoeboid ulcer
   This is an irregularly lobulated extensive but frequently shallow ulcer with a minimum width of 2 mm. The edges are irregular and sharply defined, and the surrounding epithelium is opaque. The base of the ulcer is yellowish-grey and the stroma shows varying degrees of infiltration and oedema. There is always an associated uveitis, often with a hypopyon. The edges of the ulcer stain with rose Bengal, and the base with fluorescein
   AUS   — amoeboid ulcer treated with steroids in the past week
   DU    — dendritic ulcer
   This is a characteristic zig-zag, linear, or complicated arborescent ulcer typically less than 1 mm broad, with an irregular sharply
4. Corneal stroma, uvea and sclera

**DK** — disciform keratitis (herpetic)
A central localized disc-shaped stromal keratitis occurring typically after superficial herpetic ulceration, or as a primary event in the absence of other systemic disease such as zoster, varicella, vaccinia, or mumps. The associated anterior uveitis may be very mild or severe.

**DKU** — disciform kerato-uveitis
Disciform keratitis with more than 1+ flare and 1+ cells in the anterior chamber.

**DUS** — dendritic ulcer treated with steroids in the past week

**DURC** — dendritic ulcer, recrudescent
A recrudescent ulcer is one that reappears at the site of a previous ulcer within 14 days of healing.

**DURR** — dendritic ulcer, recurrent
A recurrent ulcer is one that appears more than 14 days after healing of a previous ulcer

**MAU** — herpetic marginal ulcer
A round, oval, or irregular ulcer near the limbus, the edges of which resemble those of dendritic or amoeboid ulcers. It is normally associated with considerable stromal infiltrate and conjunctival hyperaemia which does not resemble in history or appearance a 'straphylococcal marginal ulcer' and which responds to antiviral agents.

**MHU** — metaherpetic ulcer
An indolent round or oval ulcer with smooth sloping borders that do not stain with rose Bengal, occurring in a hypoaesthetic cornea overlying an area of stromal disease. There is a past history of herpetic disease. Virus cultures are typically negative.

**LU** — linear ulcer
A non-arborescent straight or curved ulcer staining brightly with rose Bengal.

**HSK** — herpetic stromal keratitis
A generalized or irregular non-disc-shaped deep keratitis almost always following herpetic ulceration. It is usually eccentrically sited in the cornea but may be very extensive. Deep stromal vascularization frequently develops.

**HSKU** — herpetic stromal kerato-uveitis
Herpetic stromal keratitis with more than 1+ cells and 1+ flare in the anterior chamber.

**HCA** — herpetic corneal abscess
Dense opaque white or yellowish infiltrate after herpetic stromal keratitis or disciform keratitis.

**HU** — herpetic uveitis
Anterior uveitis, often severe, occurring in an eye with a history of past herpetic disease but currently no active keratitis.

**HSC** — herpetic episcleritis or scleritis
Scleral or episcleral inflammation occurring in sectional or generalized pattern in association with or following known, and active, herpetic kerato-uveitis.

5. Associated conditions

**IOP** — intraocular pressure above 30 mmHg during an episode of herpetic disease.

**DE** — dry eye
Diminution of aqueous tear production, frequently associated with drug toxicity (McGill, Williams, McKinnon, Holt-Wilson, and Jones, 1974).

**CAT** — cataract
Secondary cataract after episodes of herpetic kerato-uveitis.

**AMB** — ambylopaia
Amblyopia after herpetic corneal disease in childhood.

**FK** — filamentary keratopathy
Epithelial filaments after herpetic corneal disease.

**PDT** — presumed drug toxicity
Presumed drug side-effects (for example, cataract) not otherwise categorized.

**MIS** — miscellaneous
Any ocular sign not otherwise categorized which is thought to be due to herpetic infection (for example, iris atrophy).
B. MANAGEMENT

1. Drug treatment

S — steroid
   Treated with topical steroids

IDU — treated with Idoxuridine (IDU)

IDUT — IDU toxicity
   An eye treated with IDU, usually for
   at least 10 days (but the period can
   be shorter if treatment is very
   intensive or if IDU treatment has
   been used on previous occasions),
   which demonstrates one or more of
   the following (McGill and others,
   1974; Patterson and Jones, 1967):
   lid — ptosis
   lid margin — keratinization
   — rounded edge
   — Meibomian orifice
   occlusion
   punctum — narrowing or
   occlusion
   limbus — follicles or oedema
   conjunctiva — punctate epithelial
   disease, characteristically in the in-
   terpalpebral fissure,
   staining with rose Bengal
   cornea — punctate epithelial
   keratopathy
   — flaking opaque
   epithelium, staining
   with rose Bengal
   — microcysts, some
   staining with
   fluorescein
   — sub-epithelial opacifi-
   cation and vasculari-
   zation (changes
   aggregate in a curved
   or linear fashion
   with whorl-shaped
   patterns of epithelial
   keratopathy)

indolent corneal ulcer — developing usually
   from a linear pattern of
   punctate kerato-
   pathy. It may thus
   somewhat resemble a
   dendritic ulcer and
   may progress to
   resemble a meta-
   herpetic ulcer.
   There is marked
   associated punctate
   epithelial kerato-
   pathy.

IDUR — IDU resistance
   An ulcer adequately treated with
   IDU which:
   1. is getting worse after 4 days, or
   is static after 7 days, or is
   changing shape but not healing
   by 10 days
   2. shows no sign of IDU toxicity
   3. has no significant underlying
   active infiltrate

IDUH — IDU hypersensitivity
   Contact dermatitis of the lids after
   IDU application to the eye

F3T — treated with trifluorothymidine

F3TT — F3T toxicity
   An eye treated with F3T which
   demonstrates one or more of the
   following (McGill and others, 1974):
   punctum — narrowing
   conjunctiva — punctate epithelial
   disease, characteristically in the
   interpalpebral fissure
   staining with rose Bengal
   cornea — punctate epithelial
   keratopathy
   — epithelial microcysts
   — epithelial oedema
   (Other toxic signs may be recognized
   as clinical experience with F3T
   grows. The time required for
   toxicity to develop is not yet defined)

F3TR — F3T resistance
   An ulcer adequately treated with
   F3T which:
   1. is getting worse after 4 days, or
   is static after 7 days, or is
   changing shape but not healing
   by 10 days
   2. shows no sign of F3T toxicity
   3. has no significant underlying
   active infiltrate

F3TH — F3T hypersensitivity
   Contact dermatitis of the lids after
   F3T application to the eye

AA — treated with adenine arabinoside

AAT — Ara-A toxicity
   An eye treated with Ara-A which
   demonstrates one or more of the
   following:
   conjunctiva — punctate epithelial
   disease, characteristically in the
   interpalpebral fissure,
   staining with rose Bengal
cornea — punctate epithelial keratopathy
(Other toxic signs may be recognized as clinical experience with Ara-A grows. The time required for toxicity to develop is not yet defined)

AAR — Ara-A resistance
An ulcer adequately treated with Ara-A which:
1. is getting worse after 4 days, or is static after 7 days, or is changing shape but not healing by 10 days
2. shows no sign of Ara-A toxicity
3. has no significant underlying active infiltrate

AAH — Ara-A hypersensitivity
Contact dermatitis of the lids after Ara-A application to the eye. (We have not recognized hypersensitivity to Ara-A to date.)

2. Physical treatment
DB — debridement
Simple removal of the ulcerated epithelium
CA — carbolization
Removal of the ulcerated epithelium followed by application of phenol
ID — iodization
Removal of the ulcerated epithelium followed by application of iodine
CY — cryotherapy
Application of a cryoprobe to the ulcer and surrounding area.

3. Surgery
CF — conjunctival flap
TA — tarsorrhaphy
PKP — penetrating keratoplasty
LKP — lamellar keratoplasty
AR — allograft reaction

4. Contact lens
SCL — ‘soft’ (hydrophilic) contact lens
HCL — haptic contact lens

C. CLINICAL STUDIES
1. RES — research
Patients entered into clinical drug trials or other research projects (Designated RES₁, RES₂, etc.)

Method of use of the code
Patients with herpetic ocular disease are classified according to the code and this coded summary is recorded on the cover of their case notes.

The codes relating to each significant episode of disease or treatment are recorded on a separate line opposite the date of start and finish of treatment.

For example, Fig. 1 designates a patient with three significant episodes. An initial dendritic ulcer was treated with Idoxuridine. During the course of this illness kerato-uveitis developed and the patient was treated with steroids. After a further bout of kerato-uveitis a penetrating keratoplasty was performed. A dendritic ulcer developed during treatment with steroids and IDU toxicity necessitated a change of therapy to F₃T, with the ulcer finally resolving.

Each patient’s codes are recorded on punch cards. Fig. 2 shows a punch card for the above patient. Punch cards are updated from line to line, thus the codes for the first two episodes of disease have been transferred as indicated on the right-hand column of Fig. 1.

On the reverse side of each punch card code data are recorded in the same manner as Fig. 1. Thus all code information relevant to a patient is recorded in one place. Retrieval of data is simplified and the system allows for future elucidation of associated features or patterns.

Discussion
A continuing problem for ophthalmologists treating herpetic eye disease is the difficulty in relating

<table>
<thead>
<tr>
<th>HERPES SIMPLEX CODE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name:</strong> John Citizen</td>
</tr>
<tr>
<td><strong>Start treatment</strong></td>
</tr>
<tr>
<td>4/3/73</td>
</tr>
<tr>
<td>12/10/73</td>
</tr>
<tr>
<td>12/2/74</td>
</tr>
</tbody>
</table>

**FIG. 1 Herpes simplex code**
**Summary code for ocular herpes simplex**

**FIG. 2** Two sides of punch card recording clinical features, complications, treatment, and prognosis of herpes simplex eye disease
significant events in the patient’s past to his current problems. This difficulty is compounded when several clinicians are caring for the same patient.

Since the introduction of our coding system in a busy clinic for virus diseases, all clinicians concerned have been impressed by the way in which it facilitates clinical assessment of cases. A glance at the patient’s code summary allows one to grasp important features of his past history and present situation, even if the patient is unfamiliar to the ophthalmologist.

We have the impression that a patient’s history influences the way in which a new episode of disease presents, progresses, and responds to treatment. Use of this code and the punch card or computerized cross-reference system should help to elucidate possible patterns in evolution of disease, correlations in response to therapy, or otherwise unnoticed possible adverse effects of therapy.

Summary
A code for herpetic eye disease is presented. This simplifies the management of individual patients, and the up-to-date code summary of each case is easily maintained thus facilitating assessment of interrelating factors. It is suggested that the pattern of herpetic eye disease may have prognostic and epidemiological significance. This system has simplified retrieval of such data.

The assistance of Mrs Jane Field in preparation of this manuscript is gratefully acknowledged.

References
Summary code for ocular herpes simplex.

J McKinnon, J McGill and B R Jones

Br J Ophthalmol 1975 59: 539-544
doi: 10.1136/bjo.59.10.539

Updated information and services can be found at:
http://bjo.bmj.com/content/59/10/539

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/